Mirazid alone or combined with Paromomycin in treating cryptosporidiosis parvum in immunocompetent hospitalized patients.
Sixty cryptosporidiosis patients from Mansoura University Hospitals, 36 males and 24 females, with age from few months to ten years (mean age 6.1) were divided into three cross-matched groups of 20 patients each. All patients received the glutamine-based oral rehydration solution with 111 mmol/l glutamine, 20 mg zinc acetate once a day and vitamin A supplementation (200,000 IU) once a day for 2 weeks. For cryptosporidiosis treatment, G1 received Mirazid (10 mg/kg for 2 weeks), G2 received Paromomycin (500 mg qid for 2 weeks), and G3 received a combination of Mirazid (10 mg/kg) and Paromomycin (500 mg) for two weeks. The result was assessed according to the scales: 0 = no improvement, 1 = symptoms began improvement (reduction of diarrhea frequency and stool volume, less abdominal pain, less nausea & vomiting), 2 = diarrhea eradication, 3 = weight gain, 4 = oocyst counts reduction, 5 = reduction in diarrhea and oocyst counts, 6 = eradication of diarrhea and oocysts. G3 showed significantly higher difference than G1 & G2 in the 1st week (p = .036, 0.025 respectively), no significant difference in 2nd week, a significantly higher difference than in G1 (0.003), & G2 (0.006) in 3rd week, and a significantly higher difference than G1 (0.014), & G2 (0.01) in 4th week, but without significant differences in oocyst shedding in the 3 groups.
Massoud
Ahmed M A
AM
Department of Tropical Medicine, Faculty of Medicine, Universities of Al-Azhar, Cairo, Egypt.
Hafez
Adel O
AO
Abdel-Gawad
Abdel-Gawad E
AG
El-Shazly
Atef M
AM
Morsy
Tosson A
TA
D000818:Animals; D002648:Child; D002675:Child, Preschool; D003049:Coccidiostats / Q000627:therapeutic use*; D029744:Commiphora / Q000737:chemistry*; D003457:Cryptosporidiosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008297:Male; D010270:Parasite Egg Count / Q000662:veterinary; D010303:Paromomycin / Q000627:therapeutic use*; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D016896:Treatment Outcome
D003049:Coccidiostats; D010936:Plant Extracts; D010303:Paromomycin